Home > Resources > Precision Medicine
Precision medicine (also known as personalized medicine) uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat cancer. Precision medicine includes the use of biomarkers, molecular testing, and targeted therapies to deliver a personalized approach to cancer therapy through the use of molecular and genomic information about individual cancers. The National Cancer Institute (NCI) defines precision medicine as “discovering unique therapies that treat an individual’s cancer based on the specific abnormalities of their tumor.”
As the precision medicine landscape evolves, ACCC supports the multidisciplinary cancer care team with resources in the following areas:
Related Content from ACCC
Immuno-Oncology: There’s More to Discover The latest white paper from the Institute for Clinical Immuno-Oncology (ICLIO).
ACCC and CAP TODAY webinar: CAP/AMP/IASLC Guidelines for NSCLC: Current Experience and Future Update Four national thought-leaders examine current guidelines, planned updates, and provide expert feedback on the impact of these guidelines on practices.
This webinar was originally broadcast on Nov. 30, 2016.
Delivering Pharmacogenetic Testing in the Community Setting (Oncology Issues Sept/Oct 2016) For community cancer programs interested in implementing or growing the use of pharmacogenetic testing, here are processes and lessons learned from an ACCC Cancer Program member’s pilot pharmacogenetic testing program.
Highlights of ASCO 2016 (Oncology Issues Sept/Oct 2016)
Understanding & Improving Lung Cancer Treatment in Asian Americans & Pacific Islanders in the Community Setting This white paper explores the unique challenges facing this growing patient population, including disparity and access issues, communication and cultural barriers, and issues related to lung cancer screening, management and treatment.
ORIEN: Reshaping Cancer Research & Treatment (Oncology Issues May/June 2016) The Oncology Research Information Exchange Network (ORIEN) is working to extend precision medicine cancer clinical trials to community cancer programs.
Building a Personalized Medicine Program (Oncology Issues Sept/Oct 2015) From developing a next generation sequencing panel to help physicians select the most promising therapies for individual patients to embedding a social worker in all disease-specific clinics, this program makes personalized medicine a cornerstone of the cancer service line.
How Molecular Subtyping is Changing our Understanding of Breast Cancer (Oncology Issues Sept/Oct 2015) Molecular subtyping offers advantages for breast cancer patients, cancer programs, and the healthcare community.
Molecular Testing in the Community Setting (Oncology Issues Jan/Feb 2015) Learn about results of learning labs for process improvement in molecular testing conducted at eight ACCC member programs, including key areas identified for improvement.
How Lean Methodology can Improve Molecular Testing Processes in Advanced NSCLC (Oncology Issues Jan/Feb 2015) Read how an ACCC member program conducted a pilot study using Lean methodology to evaluate molecular testing processes, identify waste, and design an improved process for advanced NSCLC in the community setting.